
Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML
August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse
Updated on: October 12,2023
26

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML
August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse
Updated on:October 12,2023
26
